drugset
drugset / Trial / NCT03841630

A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants

NCT03841630 ↗

Phase 1 Completed 45 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

This study is being conducted to determine the side effects related to LY3437943 given as a single injection under the skin to healthy participants. Blood tests will be performed to check how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of LY3437943 or placebo. The study will last up to approximately 71 days for each participant, including screening.

Timeline

Start
2019-03-13
Primary completion
2019-07-25
Completion
2019-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Retatrutide Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.